Bloomberg News

Mazor Jumps to 3-Month High as FDA Approves Brain Procedures

July 16, 2012

Mazor Robotics Ltd. (MZOR) advanced to the highest level in three months after receiving approval from the U.S. Food and Drug Administration to market its Renaissance system for brain surgery procedures.

The shares gained 9.3 percent to 4.645 shekels at the close in Tel Aviv, the highest since April 11.

To contact the reporter on this story: David Wainer in Tel Aviv at dwainer3@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net


Hollywood Goes YouTube
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus